Sign inJoin waitlistJoin the waitlist

Neeta Somaiah

Physician · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
Fox Chase Cancer Center
2006–2009
Internal Medicine
Fox Chase Cancer Center
2005–2006
Drexel University College of Medicine/Hahnemann University
2003–2005
Internal Medicine
St John's Episcopal Hospital-South Shore
2002–2003
University of Delhi
2000–2001
Doctor of Medicine
1997–2001

Research

Immuno-genomic landscape of osteosarcoma
Nature Communications · 2020 · 213 citations
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Nature Communications · 2022 · 182 citations
Universal marker and detection tool for human sarcoma circulating tumor cells
Cancer Research · 2014 · 141 citations

Alexander Lazar
43 papers · 19 as a fellow
Anthony Conley
39 papers
Christina Roland
35 papers
Shreyaskumar Patel
35 papers
RB
Robert Benjamin
32 papers
Vinod Ravi
31 papers · 7 as a resident
Wei-Lien Wang
31 papers
Dejka Araujo
25 papers
Emily Keung
24 papers · 3 as a fellow
Maria Zarzour
23 papers
Keila Torres
22 papers
John Livingston
21 papers · 2 as a fellow

Clinical trials

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2025–2032
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2034
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2021–2024
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2020–2027